Amoxicillin Sodium Amoxycillin sodium CAS NO.34642-77-8

FOB Price: USD: 0.10-0.10 /Gram Get Latest Price
Min.Order: 1 Gram
Payment Terms: L/C,D/A,D/P,T/T,
Available Specifications:
EP USP JP CP IP(0.1-0.2)Gram0.1/Gram0.1USDEP USP JP CP IP(0.3-0.4)Gram0.1/Gram0.3USDTechnical Grade(0.5-0.6)Gram0.1/Gram0.5USD

Product Details

Keywords

Amoxicillin sodium
Amoxycillin sodium
Amoxicillin

Quick Details

ProName: Amoxicillin Sodium Amoxycillin sodium
CasNo: 34642-77-8
Molecular Formula: C16H19N3NaO5S
Appearance: white powder
Application: About Chidamide Chidamide is an oral...
DeliveryTime: 7-10 Days
PackAge: 1 kgs/Tin, 25kgs/Tin
Port: Any port of China
ProductionCapacity: 1 Metric Ton/Month
Purity: 99.9%
Storage: 0-6℃ storage
Transportation: By Air, By Sea or By Courier
LimitNum: 1 Gram
Related Substances: 0.1%Max
Residue on Ignition: 0.3%Max
Heavy Metal: 5 PPM Max.
Valid Period: 36 Months
Appearance: White powder
Protein binding: 99.8%
Metabolism: Via catechol-O-methyltransferase pathw...
CAS: 743420-02-2
Formula: C22H19FN4O2
Molecular mass: 390.4102632
Routes of Absorption: Inhalation,ingestion,eye and skin abso...
Property: a light-sensitive, hygroscopic white p...
Products of Degradation:: The product itself and its products of...
General Use: subtype-selective histone deacetylase
Stability: Stable
pH: 5-6

Superiority

Chidamide
Verified By	GMP,FDA,CEP,COS,ANDA
Service	1, Professional Techincal Guidence 2, Free Sample can be supplied before commercial purchase 3, Best price based on 100% high quality guarantee 4, Lifetime customer service since first deal 5, 24*7 hours contact
Process	About Chidamide Chidamide is an orally bioavailable, low-nanomolar inhibitor of cancer-associated histone deacetylase (HDAC) enzymes with favorable pharmacology and tolerability profiles relative to existing benzamide and non-benzamide HDAC inhibitors. It targets specifically the subtype 1, 2, 3 of Class I and subtype 10 of Class IIb HDAC and is being studied in multiple clinical trials as a single agent or in combination with chemotherapeutic agents for the treatment of various hematological and solid cancers. In clinically administrated concentrations, it demonstrated a unique epigenetic mechanism of actions against tumor cell development, involving preferential induction of growth arrest and apoptosis in blood and lymphoid-derived tumor cells, activation of NK-mediated and CD8-mediated antigen-specific cellular anti-tumor immunity, differentiation of tumor stem cells, reversal of drug-resisting tumor cells and epithelia to mesenchymal transition, which are hallmarks of treatment resistance, tumor cell metastasis and recurrence. Top Pharm Chemical Group Co., Ltd, today, announced regulatory approval of Chidamide, the world first orally administrated and subtype-selective histone deacetylase (HDAC) inhibitor for relapsed or refractory peripheral T-cell lymphoma (PTCL) patients, in China on Dec. 23, 2014 by the Chinese Food and Drug Administration (CFDA). Peripheral T-cell lymphomas (PTCL) is a set of rare and heterogeneous group of mature T- and natural killer (NK)-cell neoplasms associated with poor outcome. PTCL makes up 25 percent to 30 percent of all Non-Hodgkin's lymphoma (NHL) cases in China, much higher than that seen in Western countries of 10 percent to 15 percent. The subtype distribution of PTCL is also significantly different between China and Western countries, in which extranodal NK/T-cell lymphoma, nasal type (ENKL), a subtype highly aggressive with very poor prognosis, to be the leading subtype in Chinese population."Chidamide is the first new molecular entity discovered and developed by Top-Pharm-Chemical scientists in China.The CFDA's decision to approval the world first orally administrated selective HDACi for PTCLs is an important validation of the drug's therapeutic potential for this urgent medical need for Chinese PTCLs patients. The orally administrated Chidamide not just will provide affordable innovative treatment for the Chinese patients whom otherwise have no option to obtain most up-to dated new treatment beyond conventional chemotherapies, but also have great potential, based on its unique epigenetic mechanism of actions and existing knowledge from the field, to be easily combined with other treatment modalities in comprehensive control and management of cancer patients in fight against drug resistance and tumor recurrence,"

Details

Product Details

About Chidamide

Chidamide is an orally bioavailable, low-nanomolar inhibitor of cancer-associated histone deacetylase (HDAC) enzymes with favorable pharmacology and tolerability profiles relative to existing benzamide and non-benzamide HDAC inhibitors. It targets specifically the subtype 1, 2, 3 of Class I and subtype 10 of Class IIb HDAC and is being studied in multiple clinical trials as a single agent or in combination with chemotherapeutic agents for the treatment of various hematological and solid cancers. In clinically administrated concentrations, it demonstrated a unique epigenetic mechanism of actions against tumor cell development, involving preferential induction of growth arrest and apoptosis in blood and lymphoid-derived tumor cells, activation of NK-mediated and CD8-mediated antigen-specific cellular anti-tumor immunity, differentiation of tumor stem cells, reversal of drug-resisting tumor cells and epithelia to mesenchymal transition, which are hallmarks of treatment resistance, tumor cell metastasis and recurrence.

Top Pharm Chemical Group Co., Ltd, today, announced regulatory approval of Chidamide, the world first orally administrated and subtype-selective histone deacetylase (HDAC)

inhibitor for relapsed or refractory peripheral T-cell lymphoma (PTCL) patients, in China on Dec. 23, 2014 by the Chinese Food and Drug Administration (CFDA).

Peripheral T-cell lymphomas (PTCL) is a set of rare and heterogeneous group of mature T- and natural killer (NK)-cell neoplasms associated with poor outcome.

PTCL makes up 25 percent to 30 percent of all Non-Hodgkin's lymphoma (NHL) cases in China, much higher than that seen in Western countries of 10 percent to 15 percent.

The subtype distribution of PTCL is also significantly different between China and Western countries, in which extranodal NK/T-cell lymphoma, nasal type (ENKL),

a subtype highly aggressive with very poor prognosis, to be the leading subtype in Chinese population."Chidamide is the first new molecular entity discovered and developed by Top-Pharm-Chemical scientists in China.The CFDA's decision to approval the world first orally administrated selective HDACi for PTCLs is an important validation of the drug's therapeutic potential for this

urgent medical need for Chinese PTCLs patients. The orally administrated Chidamide not just will provide affordable innovative treatment for the Chinese patients whom otherwise have no

option to obtain most up-to dated new treatment beyond conventional chemotherapies, but also have great potential, based on its unique epigenetic mechanism of actions and existing knowledge from the field,

to be easily combined with other treatment modalities in comprehensive control and management of cancer patients in fight against drug resistance and tumor recurrence,"

Chidamide ：A Novel Subtype Selective HDAC Inhibitor Functioning as an Epigenetic Modulator Chidamide is a Class I HDAC inhibitor being studied in multiple clinical trials as a single agent or in combination with chemotherapeutic agents for the treatment of various hematological and solid cancers. Its anticancer effects are thought to be mediated through multiple mechanisms of action, including the inhibition of cell proliferation, induction of apoptosis, inhibition of epithelial to mesenchymal transition (EMT, a process that is highly relevant to tumor cell metastasis and drug resistance), induction of tumor specific antigen and antigen-specific T cell cytotoxicity, enhancement of NK cell anti-tumor activity, induction of differentiation, and resensitization of tumor cells that have become resistant to anticancer agents such as platinums, taxanes and topoisomerase II inhibitors.

Chidamide in Clinical development
1 Monotherapy against NHL T lymphoma
PTCL: Completed in Q2, 2012，NDA in Q1, 2013 (twice weekly schedule at 30mg, no drug holiday, efficacy comparable
with other approved PTCL treatments but with significant better tolerability in patients)
CTCL: Expected to be completed in Q3, 2013, NDA in Q4, 2013
2 Combined therapy against NSCLC (plus PC)
phase Ib completed in Q1, 2012 (potential benefit for patients with brain metastasis)
phase II initiated in Q4, 2012 (patients with EGFR and ALK wild type, and E-Cad for subgroup analysis)
3 International development
phase I completed in Q3, 2012 in US

Packaging

The packaging can be customized, normally, 1kgs/Tin, or 5kgs/Tin or per drums

Company Introduction

Top Pharm Chemical Group is specialized in the New Drug Researching and Developing, and mainly manufacture

Chemical Intermediates, Pharmaceutical APIs and Pilot Production. To meet customers regulatory needs,

we can offer products from gram to kilo and tons scale, and we can also support our customers

with the DMF and other documents to Complete the registration.

Our Targets:

"Best Technic; Better Quality; Better Price; Better Service"

Company Profile

Top Pharm Chemical is a leading integrated biotech company specialized in discovery and development of

novel small molecule pharmaceuticals. The company has utilized its proprietary chemical genomics-based discovery platform to successfully develop a portfolio of clinical and preclinical stage programs in a number of therapeutic areas. Our core competence is the science-driven approach in discovery, strong pipeline building capability, experience with IP, and regulatory expertise.

Top Pharm Chemical's business strategy is to generate differentiated drug candidates across multiple therapeutic

areas. Drug candidates are either developed by Top Pharm Chemical or co-developed and commercialized in a partnership at the research, preclinical and clinical stages.

Top Pharm Chemical was established as Sino-foreign joint venture in 2001 by several highly regarded Chinese returnees from the United States with academic, scientific, and industrial experience. Our founders established our company out of a common vision to create the leading drug discovery and pharmaceutical in China.

Main Products:

Anidulafungin,Micafungin,Caspofungin,Posaconazole etc. (Anti-Infective)

Ixabepilone, Argatroban, Decitabine, Everolimus etc. (Anti-Tumor)

Epothilone B, Tacrolimus, Rapamycin,Temsirolimus etc. (Fermentation)

Bimatoprost, Latanoprost, Travoprost, Cloprostenol etc.(Prostaglandins)